Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors - PubMed
6 hours ago
- #Ovarian cancer
- #Targeted therapy
- #Antibody-drug conjugate
- EGFR is frequently expressed in ovarian cancer but remains an underexplored therapeutic target.
- Cetuximab-based ADCs with payloads (DM1, DXd, MMAF) were evaluated for efficacy against ovarian cancer.
- MMAF-conjugated ADCs, especially cetuximab-vc-MMAF, showed superior antiproliferative effects in high-EGFR-expressing cells.
- Cetuximab-vc-MMAF demonstrated rapid internalization, lysosomal trafficking, and induced G2/M arrest, DNA damage, and apoptosis.
- In vivo studies confirmed cetuximab-vc-MMAF's tumor growth inhibition, prolonged survival, and selective intratumoral accumulation without systemic toxicity.
- The findings support further preclinical and clinical development of EGFR-targeting ADCs for ovarian cancer.